Robeco Institutional Asset Management
CRSP icon

Robeco Institutional Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Robeco Institutional Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-14,948
Closed -$663K – 970
2018
Q3 		$663K Sell
14,948
-16,064
-52% -$841K ﹤0.01% 799
2018
Q2 		$1.82M Buy
+31,012
New +$1.77M 0.01% 673

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Robeco Institutional Asset Management's CRSP Position: Q4 2018 in Review

Robeco Institutional Asset Management sold out of CRISPR Therapeutics (CRSP) in Q4 2018, closing a stake of 14,948 shares — an estimated $663K sold.

Robeco Institutional Asset Management first reported a position in CRSP in Q2 2018 and held it in 2 quarters. The position peaked at $1.82M in Q2 2018. 155 funds tracked by Wall St. Rank hold CRSP as of Q4 2018.

  • Robeco Institutional Asset Management reported no remaining CRISPR Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Robeco Institutional Asset Management sold 14,948 CRISPR Therapeutics shares in Q4 2018, an estimated $663K.
  • Robeco Institutional Asset Management first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 2 quarters.
  • Robeco Institutional Asset Management's CRISPR Therapeutics position peaked at $1.82M in Q2 2018.
  • 155 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2018.

Based on Robeco Institutional Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.